These results indicate that brucellosis patients at the acute stage exhibited S100A8/A9‐TLR4‐inflammatory traits, highlighting the significance of S100A8/A9 for developing effective therapeutic approaches to mitigate immunopathogenesis in acute brucellosis patients. This evidence concerns the gene TLR4 and brucellosis.